References:

1) Lesko L. J. and Sahajwalla C.,**2004**,Introduction to drug Development and Regulatory Decision-Making, *New Drug Development* ,Ed - Sahajwalla C, 1-4.
2) Ahuja S. **2001**, Modern Pharmaceutical Analysis: An Overview, Handbook of Modern Pharmaceutical Analysis, Ed – Ahuja S., Scypinski S.
3) Skoog D.A, West D.M, Holler J.F **1996**, *Fundamentals of Analytical Chemistry*, 7th Edition, Ed-Skoog D.A.
4) United States Pharmacopeia **2006** General Chapters: (1086) Impurities in official articles.
5) Bakshi M., Singh S., **2002**, Development of validated stability-indicating assay methods—critical review, Journal of Pharmaceutical and Biomedical Analysis, 1011-1040.
6) Ma M.C., Lin R., Liu J., **1999**, Statistical evaluations of dissolution similarity, Statistica Sinica **9**, 1011-1027.
7) Qureshi S.A., **2006**, Developing discriminatory drug dissolution tests and profiles: Some thoughts for consideration on the concept and its interpretation, Dissolution technologies, 18- 23.
8) Brown W. E., **2005**, Compendial requirements of dissolution testing – European Pharmacopeia, Japanese Pharmacopeia, United States Pharmacopeia, *Pharmaceutical dissolution testing*, Ed – Dressman J. & Kramar J. 73-74.
9) Brown C.K., Chokshi H.P., Nickerson B., Reed R.A., Rohars B.R., Shah P.A., **2004** , Acceptable Analytical Practices for Dissolution Testing of Poorly Soluble Compounds. Pharmaceutical technology, 56-65.
10) Wong W.W., Datla A., **2005**, Assay and Stability testing, *Handbook of Pharmaceutical analysis by HPLC*, Ed – Ahuja S. & Dong M.W.
11) Impurities in new drug substances Q3A (R2), **2006**, ICH harmonized tripartite guideline.
12) Impurities in new drug products Q3B (R2), **2006**, ICH harmonized tripartite guideline.
13) Klein S., **2010,** The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug, Ed - Klein S., American Association of Pharmaceutical Scientists, **12**, 3, 397 -406.
14) Gowthamarajan K., Singh S.K., **2010**, Dissolution testing for poorly soluble drugs: a continuing perspective, Dissolution technologies, 24-32.
15) Introduction to Spectroscopy, Third edition **2001**, Ed – Pavia D.L., Lampman G.M., Kriz G.S.
16) Snyder L.R, Kirkland J.J, Glajch, **1997,** Practical HPLC Method Development 2nd Edition, 1-21,

17) Wang Q., **2009**, Biorelevant dissolution: methodology and application in drug development, Dissolution technologies, 6-12.
18) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), **1997**, guidance for industry, Dissolution testing for immediate release solid oral dosage forms.
19) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), **2000**, guidance for industry Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System.
20) Anand O., Yu L.X., Conner D.P., Davit B.M., **2011,** Dissolution Testing for Generic Drugs: An FDA Perspective, American Association of Pharmaceutical Scientists, **13**, 328-335.
21) United States Pharmacopeia **2006** General Chapters: (711) Dissolution
22) United States Pharmacopeia **2006** General Chapters: (724) Drug release
23) United States Pharmacopeia **2006** General Chapters: (1092) the dissolution procedure: Development and validation.
24) Patil P.B., Gupta V.R.M., Udipi R.H., Srikanth K., Prasad B.S.G.,**2010**, Development of dissolution medium for poorly water soluble drug mefenamic acid , Research Journal of Pharmaceutical, Biological and Chemical Sciences Development, **1**(4), 544-549.
25) Bajerski L., Rossi R.C., Dias C.L., Bergold A.M., Fröehlich P.E., **2010**, Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial Tablets., American Association of Pharmaceutical Scientists, **2**, 637-644
26) Syal P.K., Sahoo M., Ingale K.D., Ingale S. S., Choudhari V. P., Kuchekar B. S. , **2010**, Development and validation of a RP-HPLC-PDA method for simultaneous estimation of Drotaverine and Etoricoxib in tablet and its application for dissolution studies, Der Pharma Chemica**, 2(4)**: 93-102,
27) Gupta A., Gaud R.M., Ganga S., **2010**, Development of Discriminating Dissolution Method for an Insoluble Drug: Nisoldipine, International Journal of Pharmtech Research, **2(1),** 931-939.
28) Miyawa J.H., Schulman S.G., **2002**, Ultraviolet - Visible spectrophotometry, *Handbook of Pharmaceutical analysis*, Ed – Ohannesian L. & Streeter A.J.
29) Mishra A.K., Kumar M., Mishra A., Verma A., Chattopadhyay T., **2010**, Validated UV spectroscopic method for estimation of salbutamol from tablet formulations. Archives of applied science research, **2(3),** 207-211.

30) Baertschi S.W. and Jansen P.J., **2005**, Stress Testing: A Predictive Tool, Pharmaceutical Stress Testing Predicting Drug Degradation, Ed- Baertschi S.W., 13-15.
31) Nagpal S., Karan, Upadhyay A., Bhardwaj T. R. , Thakkar A, **2011**, A Review on Need and Importance of Impurity Profiling, Current Pharmaceutical Analysis, **7**, 62-70
32) Verbeken M., Suleman S., Baert B., Vangheluwe E., Dorpe S.V., Burvenich C., **2011**, Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine, Verbeken et al. Malaria Journal, **10:51**, 1-9.
33) Pilaniya K., Chandrawanshi H.K., Pilaniya U., Manchandani P., Jain P., Singh N., **2010**, Recent trends in the impurity profile of pharmaceuticals, J Adv Pharm Technol Res.,**1(3)**: 302–310.
34) Klick S., Muijselaar P.G., Waterval J., Eichinger T., Korn C., Gerding T.K, Debets A.J., Griend C.S.V, Beld C.V., Somsen G.W., DeJong G., **2005**, Toward a Generic Approach for Stress Testing of Drug Substances and Drug Products, Pharmaceutical Technology, 48-57
35) Stability testing of new drug substances and new drug products Q1A (R2), **2003**, ICH harmonized tripartite guideline.
36) Validation of Analytical Procedures: Text and Methodology Q2 (R1), ICH Harmonised Tripartite Guideline.